[1]李中万 杨广钢 姚丽云 徐绍俊△ 付小勇 潘永雄.健肾方联合唑来膦酸治疗绝经后骨质疏松的临床观察[J].中国中医骨伤科杂志,2018,26(07):25-28.
　LI Zhongwan YANG Guanggang YAO Liyun XU Shaojun FU Xiaoyong PAN Yongxiong.Clinical Observation of Renal Tonal Prescription Combined with Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2018,26(07):25-28.
点击复制

健肾方联合唑来膦酸治疗绝经后骨质疏松的临床观察()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第26卷
期数:
2018年07期
页码:
25-28
栏目:
临床研究
出版日期:
2018-07-02

文章信息/Info

Title:
Clinical Observation of Renal Tonal Prescription Combined with Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis
文章编号:
1005-0205(2018)07-0025-04
作者:
李中万1 杨广钢1 姚丽云1 徐绍俊1△ 付小勇1 潘永雄1
1广州市正骨医院(广州,510045)
Author(s):
LI Zhongwan1 YANG Guanggang1 YAO Liyun1 XU Shaojun1△ FU Xiaoyong1 PAN Yongxiong1
1Guangzhou Orthopedic Hospital,Guangzhou 510045,China.
关键词:
健肾方;  唑来膦酸;  骨密度;  骨质疏松症;  骨保护素
Keywords:
Keywords: renal tonal prescription;  zoledronic acid;  bone mineraldensity;  osteoporosis;  osteoprotegerin
分类号:
R274.39
文献标志码:
A
摘要:
目的:评价健肾方联合唑来膦酸治疗绝经后骨质疏松的临床疗效。方法:选取2016年1月至2017年2月于本院就诊的绝经后骨质疏松症女性患者共80例,随机分为联合组和对照组,联合组采用健肾方联合唑来膦酸进行治疗,对照组仅采用唑来膦酸治疗,对比两组患者治疗前、治疗后6个月的骨密度和临床症状,比较两组的血清E2,OPG和IGF-Ⅰ水平。结果:两组患者治疗前的T值对比差异无统计学意义(t=1.360,P=0.178),治疗后6个月联合组的T值显著高于对照组,差异有统计学意义(t=7.227,P<0.01); 两组患者治疗前的VAS评分对比差异无统计学意义(t=0.320,P=0.750),治疗后6个月联合组的VAS评分显著低于对照组,差异有统计学意义(t=5.597,P<0.01); 治疗后6个月联合组的血清E2,OPG和IGF-Ⅰ水平均显著上升,差异有统计学意义(P<0.05),而对照组的血清OPG和IGF-Ⅰ水平也显著上升,差异有统计意义(P<0.05),治疗后6个月联合组的血清E2,OPG和IGF-Ⅰ水平均显著高于对照组,差异具有统计学意义(P<0.05); 两组不良反应发生情况对比差异无统计学意义(χ2=0.721,P=0.396)。结论:健肾方联合唑来膦酸治疗绝经后骨质疏松症患者,能显著提高其骨密度和缓解疼痛,同时能促进雌性激素的提高和骨形成,临床应用安全性良好。
Abstract:
Abstract Objective:To evaluate the clinical effect of renal tonal prescription combined with zoledronic acid in the treatment of postmenopausal osteoporosis.Methods:A total of 80 patients with postmenopausal osteoporosis were randomly divided into two groups:combined group and control group(n=40 for each group).The control group was treated with zoledronic acid only,and the combined group were treated with renal tonal prescription combined with zoledronic acid.The bone mineral density and clinical symptoms were compared between the two groups before treatment and 6 months after treatment.Serum E2,OPG and IGF-I levels were also compared between the two groups.Results:There was no significant difference in T value between the two groups before treatment(t=1.360,P=0.178).The T value of the combined group was significantly higher than that of the control group after 6 months(t=7.227,P<0.01).There was no significant difference between the two groups in the VAS score before treatment(t=0.320,P=0.750),the VAS score of the combined group was significantly lower than that of the control group(t=5.597,P<0.01).The levels of serum E2,OPG and IGF-I were significantly increased in the combined group 6 months after treatment,and the levels of serum OPG and IGF-Ⅰ in the control group were significantly increased(P<0.05),and the levels of serum E2,OPG and IGF-Ⅰ in the combined group were significantly higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ2=0.721,P=0.396).Conclusion:Renal tonal prescription combined with zoledronic acid in the treatment of postmenopausal osteoporosis can significantly improve its bone density and relieve pain,and promote the improvement of estrogen and bone formation,and the clinical application is safe.

参考文献/References:

[1] Black DM,Rosen CJ.Clinical Practice. Postmenopausal Osteoporosis[J]. N Engl J Med,2016,374( 3):254-262.
[2] Liu HF,Liu Y,Yang L,et al. Pulse electromagnetic field treatment curative effect observation of postmenopausal osteoporosis[J]. Journal of biomedical engineering,2014,31(1):48-52.
[3] 覃裕,邱冰,朱思刚,等.唑来膦酸盐联合脉冲电磁场治疗绝经后骨质疏松症的临床疗效分析[J].中国骨质疏松杂志,2015,21(8):945-948.
[4] 吴海洋,索欢,王平.绝经后骨质疏松症的临床中药治疗进展[J].中国骨质疏松杂志,2015,21(2):241-244.
[5] 李保林,利云峰,谭建伟,等.健肾方冲剂对绝经后骨质疏松性腰椎骨折患者的骨代谢指标影响[J].中医正骨,2007,19(9):4-5.
[6] 葛继荣,郑洪新,万小明,等.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015,21(9):1023-1028.
[7] Crandall CJ,Newberry SJ,Diamant A,et al.Comparative effectiveness of pharmacologic treatments to prevent fractures:an updated systematic review[J].Ann Intern Med,2014,161( 10):711- 723.
[8] James SJ,Mirza SB,Culliford DJ,et al.Baseline bone mineral density and boneturnover in pre-operative hip and knee arthroplasty patients[J].Bone Joint Res,2014,17( 1):14-19.
[9] Zhao WC,Song LJ,Wen KH,et al.Research progress of longspur epimedium for anti-osteoporosis[J].China Medical Herald,2012,25:20-22.
[10] 曾湘骏,何健东,阙敏强,等.健肾方治疗老年人工髋关节置换术后股骨端假体周围骨质疏松[J].中医药临床,2016,28(8):1142-1145.
[11] 徐伟锋,叶健,吴连国.强骨饮对骨质疏松性股骨颈骨折患者全髋关节置换术后血清骨代谢生化指标和骨密度的影响[J].中医正骨,2015,27(2):12-16.
[12] 闫欣.威灵仙外用对小鼠致痛模型的影响[J].河南职工医学院学报,2013,25(5):551- 554.
[13] 苗明三,于舒雁,魏荣瑞.不同品种威灵仙外用抗炎镇痛作用研究[J].时珍国医国药,2014,25(8):465-470.
[14] 甄朋超,王倩倩,刘钢.夏季贴敷膏治疗膝关节骨性关节炎(膝痹病-风寒湿痹型)的临床观察[J].中国中医骨伤科杂志,2017,25(12):21-23.
[15] 周明旺,王晓萍,李盛华.中医药在膝骨性关节炎治疗中的应用现状[J].中国中医骨伤科杂志,2015,23(4):75-78.
[16] 曾春兰,钟正贤,卢文杰,等.大叶千斤拔的药理作用研究[J].中医药导报.2011,17(7):79-81.
[17] 周菊峰,黄兰芳,胡伟,等.气相色谱/质谱和化学计量学解析法用于千斤拔挥发性成分的分析[J].药物分析杂志,2011,31(7):1308-1312.

备注/Memo

备注/Memo:
基金项目:广东省中医药局科研课题(20172116) △通信作者 E-mail:290936029@qq.com
更新日期/Last Update: 2018-07-02